Human ILC1s Target Leukemia Stem Cells and Control Development of AML

干细胞 免疫学 髓系白血病 白血病 医学 髓样 CD33 移植 癌症研究 川地34 内科学 肿瘤科 生物 遗传学
作者
Zhenlong Li,Hejun Tang,Victoria Chen,Rui Ma,Jianying Zhang,Guido Marcucci,Jianhua Yu,Michael A. Caligiuri
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 886-886
标识
DOI:10.1182/blood-2023-190767
摘要

Acute myeloid leukemia (AML) is a devastating disease with a median 5-year survival of only 40-45% for patients younger than age 65 who are treated with standard chemotherapy. Although in some cases allogeneic stem cell transplantation has proven to be curative, the treatment-related mortality and the risk for disease relapse due to persistence of leukemia stem cells (LSCs) remains relatively high. Therefore, safer and more effective novel therapeutic approaches are needed to improve the clinical outcomes of patients with AML. Innate lymphoid cell (ILC) is critical in mediating immune responses and regulating tissue homeostasis and inflammation. We recently reported that mouse ILC1s contribute to the control of AML by eliminating LSCs and inhibiting their differentiation into myeloid blasts, and functional impairment of mouse ILC1s in AML leads to the outgrowth of LSCs and disease relapse (Li et al., Nature Immunology. 2022). However, the full role and mechanistic characterization of human ILC1s in anti-tumor responses to AML remains to be fully explored. Upon analysis of ILC1s in the blood of patients with AML at the onset of disease, we observed a highly significant reduction in the total ILC1s count among lineage-negative cells (Lin −, defined asdepletion of CD3, CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD33, CD34, CD203c, FceRI, and CD56 positive cells) relative to healthy donors ( p = 0.031, n = 6 healthy donors; n = 4 patients with AML). Further, functional ILC1s positive for IFNγ and DNAM-1 were significantly reduced in the patients with AML compared to healthy donors. Analysis of 106 AML cases from the Cancer Genome Atlas (TCGA) showed that AML patients with a high ILC1 gene signature had a significantly prolonged overall survival compared to AML patients with a low ILC1 gene signature. By directly interacting with LSCs, human ILC1s can eliminate LSCs via the production of IFNγ. Through Wright-Giemsa staining, we observed that ILC1s blocked the differentiation of CD34 +CD38 − cells into macrophage-like leukemia-supporting cells, which were previously reported to support the growth of leukemic cells rather than inhibit them. Flow cytometry of these differentiated cells showed that some exhibited the tumor-promoting phenotype with expression of CD11b and CD206. These macrophage-like leukemia-supporting cells significantly decreased when co-cultured with ILC1s. This differentiation is at least partially dependent on TNF secreted by ILC1s. We also performed an in vivo transplantation experiment, in which human CD34 +CD38 − cells and human ILC1s were co-injected intravenously (i.v.) into NOD.Cg- Prkdc scid Il2rg tm1WjlTg (NSG-SGM3) mice that express human IL3, GM-CSF, and SCF to support the stable engraftment of myeloid lineages. Injection of human ILC1s from healthy individuals reduced the LSC engraftment into these mice and suppressed the progression of AML. This was evidenced by a significant decrease in the number of CD45 +CD33 + blast cells, CD34 +CD38 − LSCs, and significantly prolonged survival of the mice ( p = 0.0118, n = 5/group). These results were all in comparison to mice that did not receive an injection of ILC1s. Although ILC1s target LSCs, they have no toxicity on normal HSCs. For a therapeutic purpose, we were able to derive ILC1s from umbilical cord blood (UCB) CD34 + hematopoietic stem cells (HSCs) with over 700-fold expansion and the expanded ILC1s demonstrate authentic ILC1 phenotypes and functions. Moreover, arming the expanded ILC1s with a chimeric antigen receptor (CAR) targeting FLT3, which we previously constructed (Chen et al., Leukemia. 2017), enhanced their effector function. In conclusion, ILC1s in patients with AML are impaired, while a high expression of the ILC1 gene signature is associated with better overall survival. Human ILC1s can both eliminate LSCs via production of IFNγ and block LSC differentiation into tumor-promoting macrophage-like cells through TNF. These effects converge to limit leukemogenesis in vivo. The use of UCB CD34 + HSCs to generate ILC1s, especially after being engineered with a CAR, could allow for a readily available supply of ILC1s to be produced for human adoptive transfer studies. Our findings provide evidence that targeting human ILC1s may be a promising therapeutic approach for extending disease-free survival in patients with AML.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助可乐采纳,获得10
刚刚
LSJ完成签到,获得积分10
刚刚
何毅发布了新的文献求助10
刚刚
猪猪hero发布了新的文献求助10
1秒前
北赊完成签到,获得积分10
1秒前
1秒前
1秒前
好奇宝宝发布了新的文献求助10
2秒前
2秒前
小二郎应助霸王萝卜丝采纳,获得10
2秒前
Zing完成签到,获得积分10
3秒前
allglitters发布了新的文献求助10
3秒前
3秒前
咚咚发布了新的文献求助10
3秒前
4秒前
瘦瘦依白发布了新的文献求助30
5秒前
5秒前
乖猫要努力应助zero桥采纳,获得20
5秒前
欢喜的天空完成签到,获得积分20
5秒前
5秒前
6秒前
大模型应助含蓄海白采纳,获得10
6秒前
6秒前
shuo完成签到,获得积分10
7秒前
7秒前
小宋爱睡觉完成签到,获得积分10
7秒前
慕青应助mumu0822采纳,获得10
8秒前
猪猪hero发布了新的文献求助10
9秒前
renyi97发布了新的文献求助10
9秒前
小二郎应助何毅采纳,获得10
10秒前
shuo发布了新的文献求助10
10秒前
10秒前
叶琳发布了新的文献求助10
11秒前
治愈小羊完成签到,获得积分10
11秒前
11秒前
11秒前
11秒前
Zxffei完成签到,获得积分10
11秒前
11秒前
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971277
求助须知:如何正确求助?哪些是违规求助? 3516009
关于积分的说明 11180382
捐赠科研通 3251075
什么是DOI,文献DOI怎么找? 1795664
邀请新用户注册赠送积分活动 875988
科研通“疑难数据库(出版商)”最低求助积分说明 805209